Project Grant HT94252410686
Award Date 8/1/24
Completion Date 7/31/28
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
- The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
- The University of Texas MD Anderson Cancer Center was awarded a $1,214,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to identify collateral lethal targets in prostate cancer from September 1, 2021 through August 31, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
- The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, received a $486,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, with a start date of September 30, 2023, supports research targeting the PRMT5 protein in melanoma with MTAP gene loss. The funding will enable preclinical studies, including evaluating novel treatments, to advance the understanding and...
- This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
- This $1,626,438.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by the University of Texas MD Anderson Cancer Center (MD Anderson) to transform healthcare for military service members, veterans, and the broader public. The award will fund MD Anderson's comprehensive cancer research efforts, spanning basic, applied, and translational stages, with a focus on developing novel...
- The Department of the Army Medical Command awarded a $580,444 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. The grant will fund research from August 15, 2022 to August 14, 2025 to target STAT3 signaling pathways to promote recovery from neuropathic pain. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving military and public...
- This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
- The University of Texas MD Anderson Cancer Center will receive $729,000 through a Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 2021 through August 2025 to translate novel discoveries in gastric adenocarcinoma biology into therapeutic advances. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...